The ASCO Post
ascopost.com
Actively hiring
Publishing
Higher Education
Health Care
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Overview
About About The ASCO Post Editorial Board Rights and Permissions Contact Subscribe News FDA Update Journal Spotlight Expert's Corner In the Clinic View By Issue View All Meetings IASLC WCLC 2026 2026 ASCO GI ASCO Breakthrough 2026 ASCO 2026 ESTRO 2026 Calendar View All Topics AI in Oncology Breast…
News
'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly - The ASCO Post
In a study of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, 6 months of treatment with the anti-PD-1 agent dostarlimab-gxly alone led to clinical complete responses in...
Read more
Report
Report
Report